International Biotech: Accessing the U.S. Capital Markets in a Post-COVID-19 World
Through the coronavirus pandemic, biotech companies have continued to innovate and are turning U.S. capital markets to finance their vision and innovation.
International Biotech: Accessing the U.S. Capital Markets in a Post-COVID-19 World
International Biotech: Accessing the U.S. Capital Markets in a Post-COVID-19 WorldJuly 2020 – Biotech innovations are continuing to advance during the coronavirus pandemic — and many companies are now turning to U.S. capital markets for financing. During this call, a panel of capital markets and biotech experts discussed developments in today’s rapidly changing environment.
Topics covered include:
- The latest capital markets updates
- Strategies for outreach to the world’s most sophisticated investors
- Other issues impacting biotech IPOs, including the upcoming election and an increase in SPAC transactions